soul trial oral semaglutide cardiovascular outcomes 2025 results Abstract 4351008: Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies SOUL: Oral Semaglutide Cuts CV

In contrast, observational studies show a consistent association between GLP-1RA use and lower rates of alcohol-related events, particularly for chronic AUD outcomes, although the observational design precludes firm causal inference

Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain

Ileus Compared to Gastroparesis Projected Settlement Ranges No GLP-1 settlement has been reached

Diabetes, Obesity and Metabolism, 26(10), 4480-4489

Bottom line: While you might retain some benefits with every-other-week dosing, the risk of weight regain and the return of intense hunger is much higher compared to a weekly schedule